Literature DB >> 12922122

Evaluation of Venezuelan Equine Encephalitis (VEE) replicon-based Outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease.

Clay L Gipson1, Nancy L Davis, Robert E Johnston, Aravinda M de Silva.   

Abstract

Venezuelan Equine Encephalitis (VEE) virus replicon particles (VRPs) encoding Borrelia burgdorferi Outer surface protein A (OspA) were evaluated for their ability to induce an immune response and provide protection from tick-borne spirochetes. VRPs expressing ospA that accumulated intracellularly (VRP OspA) or that was secreted from host cells (VRP tPA-OspA) were tested. Both VRP OspA and VRP tPA-OspA expressed ospA in immunized mice. Mice vaccinated with VRPs expressing secreted OspA produced significant amounts of anti-OspA antibodies, whereas VRPs expressing intracellular OspA were less immunogenic. The VRP method of delivery induced a Th1 type immune response unlike the recombinant OspA protein in Freund's adjuvant, which induced a mixed (Th1 and Th2) immune response. The VRP tPA-OspA construct induced an immune response that reduced the bacterial load in feeding Ixodes scapularis and blocked transmission to the host. These results indicate that VRPs are capable of providing protection against tick-borne B. burgdorferi, and potentially can be used for developing improved vaccines against Lyme disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922122     DOI: 10.1016/s0264-410x(03)00307-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.

Authors:  Debaditya Bhattacharya; Joan Mecsas; Linden T Hu
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

2.  Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

Authors:  Mark R Scheckelhoff; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2005-11-04       Impact factor: 3.641

3.  Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine.

Authors:  Manish Kumar; Simarjot Kaur; Toru Kariu; Xiuli Yang; Ioannis Bossis; John F Anderson; Utpal Pal
Journal:  Vaccine       Date:  2011-09-21       Impact factor: 3.641

4.  Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza.

Authors:  Victor C Huber; Raelene M McKeon; Martha N Brackin; Laura A Miller; Rachael Keating; Scott A Brown; Natalia Makarova; Daniel R Perez; Gene H Macdonald; Jonathan A McCullers
Journal:  Clin Vaccine Immunol       Date:  2006-09

5.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

6.  Vaccination of mice with gonococcal TbpB expressed in vivo from Venezuelan equine encephalitis viral replicon particles.

Authors:  Christopher E Thomas; Weiyan Zhu; Cornelius N Van Dam; Nancy L Davis; Robert E Johnston; P Frederick Sparling
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

7.  A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen.

Authors:  Sa Xiao; Manish Kumar; Xiuli Yang; Mustafa Akkoyunlu; Peter L Collins; Siba K Samal; Utpal Pal
Journal:  Vaccine       Date:  2011-05-19       Impact factor: 3.641

Review 8.  Recombinant vectors as influenza vaccines.

Authors:  Sarah A Kopecky-Bromberg; Peter Palese
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.